van de Wetering M D, de Witte M A, Kremer L C M, Offringa M, Scholten R J P M, Caron H N
Paediatric Oncology Department, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands.
Eur J Cancer. 2005 Jul;41(10):1372-82. doi: 10.1016/j.ejca.2005.03.006.
The use of oral prophylactic antibiotics in oncology patients is still a matter of debate. A systematic review was performed to assess the evidence for the effectiveness of oral prophylactic antibiotics to decrease bacteraemia and infection-related mortality in oncology patients during neutropenic episodes. Medline, Embase and the Cochrane register of controlled trials were searched from 1966 until 2002. The main outcome was the number of patients with documented bacteraemia (Gram-negative or Gram-positive bacteraemia) and infection related mortality. Data-extraction and quality assessment were performed independently by two reviewers. A total of 22 trials met the inclusion criteria. Seventeen trials compared prophylaxis (quinolones or Trimethoprim/sulfamethoxazole (TMP/SMZ)) to no prophylaxis. The incidence of Gram-negative bacteraemia decreased significantly (pooled OR 0.39, 95% CI 0.24-0.62) without an increase in Gram-positive bacteraemia. Quinolone-based regimens showed a stronger reduction in Gram-negative bacteraemia while TMP/SMZ based regimens were more effective in Gram-positive bacteraemia. Infection related mortality due to bacterial causes decreased with the use of prophylactic antibiotics (pooled OR 0.49, 95% CI 0.27-0.88). No increase in fungaemia or fungal related mortality was seen with the use of oral prophylaxis. In conclusion, this study has shown that oral prophylactic antibiotics decreased Gram-negative bacteraemia and infection related mortality due to bacterial causes during neutropenic episodes in oncology patients.
在肿瘤患者中使用口服预防性抗生素仍是一个有争议的问题。进行了一项系统评价,以评估口服预防性抗生素在减少肿瘤患者中性粒细胞减少期菌血症和感染相关死亡率方面有效性的证据。检索了1966年至2002年的医学期刊数据库(Medline)、荷兰医学文摘数据库(Embase)和Cochrane对照试验注册库。主要结局是有菌血症记录(革兰氏阴性或革兰氏阳性菌血症)的患者数量以及感染相关死亡率。由两名评价者独立进行数据提取和质量评估。共有22项试验符合纳入标准。17项试验比较了预防性用药(喹诺酮类或甲氧苄啶/磺胺甲恶唑(TMP/SMZ))与不进行预防性用药的情况。革兰氏阴性菌血症的发生率显著降低(合并比值比0.39,95%置信区间0.24 - 0.62),而革兰氏阳性菌血症没有增加。基于喹诺酮类的方案在降低革兰氏阴性菌血症方面效果更强,而基于TMP/SMZ的方案在革兰氏阳性菌血症方面更有效。使用预防性抗生素后,细菌引起的感染相关死亡率降低(合并比值比0.49,95%置信区间0.27 - 0.88)。使用口服预防性用药未发现真菌血症或真菌相关死亡率增加。总之,本研究表明口服预防性抗生素可降低肿瘤患者中性粒细胞减少期革兰氏阴性菌血症以及细菌引起的感染相关死亡率。